Surmodics, Inc. (NASDAQ:SRDX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02.
|
Departures of Directors or Certain Officers; |
(d) On April 12, 2017, the Board of Directors of Surmodics, Inc.
(the Company) appointed Lisa Wipperman Heine, 53, to serve
as a director of the Company, effective immediately. In
connection with this appointment, the Board also increased the
size of the Board from six to seven members. Ms. Heine will serve
on the Organization and Compensation Committee, and the Corporate
Governance and Nominating Committee of the Board. There are no
arrangements or understandings between Ms. Heine and any other
persons to which Ms. Heine was appointed a director of the
Company, nor does she have a direct or indirect material interest
in any transaction required to be disclosed to Item 404(a) of
Regulation S-K.
Ms. Heine will be compensated for her services on the Board in
accordance with the Companys Board Compensation Policy (the
Policy). to the Policy, Ms. Heine will receive an annual
cash retainer of $35,000 for her service on the board, $5,000 for
her service on the Organization and Compensation Committee, and
$4,000 for her service on the Corporate Governance and Nominating
Committee. In addition to the cash retainers, Ms. Heine was
granted an equity award having a grant date fair value of
$60,000, one-half of such award in the form of a nonqualified
stock option to purchase shares of the Companys common stock and
the other half in the form of restricted stock units. The equity
awards vest ratably on a monthly basis and will become fully
vested on the earlier of the 12-month anniversary of the grant
date, or the date of the next years annual meeting.
On April 17, 2017, the Company issued a press release announcing
Ms. Heines appointment as a director of the Company. A copy of
the press release is attached as an exhibit hereto.
| Item 9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits. |
| Exhibit Number | Description |
| 99.1 | Press Release dated April 17, 2017 |
About Surmodics, Inc. (NASDAQ:SRDX)
Surmodics, Inc. is a provider of medical device and in vitro diagnostic technologies to the healthcare industry. The Company operates through two segments: Medical Device and In Vitro Diagnostics. The Company’s Medical Device segment consists of surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices; international cardiology and peripheral balloon design, development and manufacturing, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device. The Company’s In Vitro Diagnostics segment manufactures or sells components for in vitro diagnostic immunoassay and molecular tests. The In Vitro Diagnostics segment manufactures and sells surface coatings to the diagnostic, biomedical research and life science markets. In Vitro Diagnostics segment offers protein stabilization reagents, substrates, antigens and surface coatings. Surmodics, Inc. (NASDAQ:SRDX) Recent Trading Information
Surmodics, Inc. (NASDAQ:SRDX) closed its last trading session up +1.00 at 24.35 with 65,115 shares trading hands.
